NCT05925166View on ClinicalTrials.gov

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

NANot yet recruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

December 31, 2026

Conditions

Acute Gout

Interventions

DRUG

rhTNFR-Fc

Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2

DRUG

Triamcinolone Acetonide

Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2

Trial Locations (1)

330000

Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital, Nanchang

All Listed Sponsors

lead

Lihua Duan

OTHER

NCT05925166 - Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout | Biotech Hunter | Biotech Hunter